Connelly Robert 4

4 · Elicio Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Elicio Therapeutics (ELTX) CEO Robert Connelly Receives Award

What Happened

Robert Connelly, CEO, President and Director of Elicio Therapeutics (ELTX), was granted equity awards on February 2, 2026: 73,600 restricted stock units (RSUs) and a 147,200‑share derivative award (stock options). Both awards show an acquisition price of $0.00 (no cash paid) and a reported value of $0 on the Form 4 for the grant date.
These are compensation awards (not open‑market purchases or sales) and therefore are routine equity compensation rather than an investment purchase. RSUs convert to one share per RSU when they vest; the derivative award is a stock option award that vests over time.

Key Details

Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (timely filing).
Awards: 73,600 RSUs (F1) and 147,200 derivative securities (stock options) (F2); reported price $0.00.
Vesting (per footnotes): RSUs—25% vest on Feb 2, 2027, then annual installments over the next three years; Options—25% vests on Feb 2, 2027, then the remainder vests in monthly installments over the following three years. All vesting is subject to continued service.
Shares owned after the transaction: not specified in the excerpt of the filing provided.
No 10b5-1, tax‑withholding sale, or late‑filing flags noted in this filing excerpt.

Context

RSUs provide the right to receive one share per unit upon vesting; options give the right to purchase shares subject to an exercise price and vesting schedule (this filing shows the grant and vesting terms but not exercise prices or post‑exercise actions).
These types of grants are common forms of executive compensation and do not, by themselves, indicate buying or selling sentiment in the market.

Form 4

Period: 2026-02-02

DirectorCEO, President and Director

Transactions

Award
Common Stock
[F1]
2026-02-02+73,600→ 120,570 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-02+147,200→ 147,200 total
Exercise: $8.10Exp: 2036-02-02→ Common Stock (147,200 underlying)

Footnotes (2)

[F1]Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.
[F2]The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Signature

/s/ Robert Connelly|2026-02-03

1 file